Evoke Pharma stock soars after receiving patent allowance for GIMOTI

Evoke Pharma Inc (NASDAQ:EVOK) stock surged 50% following a Notice of Allowance from the USPTO for a patent application covering its gastroparesis treatment, GIMOTI. This new patent, expected to expire in December 2036, will be listed in the FDA's Orange Book, significantly extending market exclusivity and reinforcing intellectual property protection for the company's unique FDA-approved, non-oral metoclopramide formulation. The allowance adds meaningful value to the GIMOTI franchise, which provides a crucial alternative for patients with compromised gastric absorption.

Analysis

Evoke Pharma (NASDAQ:EVOK) saw its stock surge 50% following the announcement of a Notice of Allowance from the U.S. Patent and Trademark Office for its gastroparesis treatment, GIMOTI. This development is fundamentally significant as the new patent, expected to expire in December 2036, will be listed in the FDA's Orange Book, thereby extending the drug's market exclusivity and reinforcing its intellectual property moat. This extension provides a more durable long-term revenue stream for what is the only FDA-approved, non-oral, self-administered formulation of metoclopramide, a key differentiator for patients whose condition compromises the absorption of oral medication. According to management, this allowance adds 'meaningful value' to the GIMOTI franchise. The company's proactive IP strategy is further underscored by its filing of an additional continuation application to broaden its claims, signaling a clear focus on maximizing the commercial longevity of its core asset.

Key Decisions for Investors

• Investors should re-evaluate Evoke's long-term valuation, as the newly secured patent protection for GIMOTI until 2036 significantly de-risks future revenue streams from generic competition.
• While the news is fundamentally positive, the immediate 50% share price increase suggests the market has priced in much of the near-term upside, warranting caution for new investors considering entry points.
• Monitor for key execution milestones that will solidify this value, including the final patent issuance, its official listing in the FDA's Orange Book, and the outcome of the additional patent application which could serve as a future catalyst.